Question 1

What are the potential benefits of participating in this trial compared to standard treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients clinical trial (NCT02899299). Contact the study team or your healthcare provider for specific answers.

Question 2

What side effects should I expect from the treatments being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients clinical trial (NCT02899299). Contact the study team or your healthcare provider for specific answers.

Question 3

How will my eligibility be determined, and what tests will be required?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients clinical trial (NCT02899299). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients clinical trial (NCT02899299). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients clinical trial (NCT02899299). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients clinical trial (NCT02899299). Contact the study team or your healthcare provider for specific answers.

What this study is about